The upgraded facility includes two class 10,000 clean room facilities containing class 100 clean operation areas for open procedures, one for AlloStim and the other for AlloVax.
The facility with interlocked rooms, also accommodates inventory and finished product storage, packaging, shipping, sterile system technologies and a proposed technology for a rapid microbiological method to detect product sterility failures.
ITL founder and CEO Michael Har-Noy said, "The investments in research and development and these new GMP manufacturing facilities is consistent with our strategic plan to become the world’s leading authority for the mass production and distribution of living cell products."
Up on successful completion of trial run, the facility is expected to commence operations around April 2013.
The completion and validation of the GMP manufacturing facility will enable the company to launch a phase II/III trial as planned during early 2013.